SIGA Technologies Inc. (SIGA)’s Financial Results Comparing With Dova Pharmaceuticals Inc. (NASDAQ:DOVA)

SIGA Technologies Inc. (NASDAQ:SIGA) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies Inc. 6 0.97 N/A 5.13 1.10
Dova Pharmaceuticals Inc. 9 32.94 N/A -2.66 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
SIGA Technologies Inc. 0.00% 0% 0%
Dova Pharmaceuticals Inc. 0.00% -87.2% -61.8%


The Current Ratio of SIGA Technologies Inc. is 10.2 while its Quick Ratio stands at 10. The Current Ratio of rival Dova Pharmaceuticals Inc. is 4.5 and its Quick Ratio is has 4.3. SIGA Technologies Inc. is better equipped to clear short and long-term obligations than Dova Pharmaceuticals Inc.

Institutional & Insider Ownership

SIGA Technologies Inc. and Dova Pharmaceuticals Inc. has shares held by institutional investors as follows: 30.2% and 41.7%. SIGA Technologies Inc.’s share held by insiders are 2.6%. Competitively, 49.4% are Dova Pharmaceuticals Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
SIGA Technologies Inc. 2.91% 6% -14% 12.1% -13.87% -28.48%
Dova Pharmaceuticals Inc. 14.96% 36.13% 49.16% -31.73% -56.16% 52.11%

For the past year SIGA Technologies Inc. had bearish trend while Dova Pharmaceuticals Inc. had bullish trend.


SIGA Technologies Inc. beats Dova Pharmaceuticals Inc. on 5 of the 8 factors.

SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.